Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Afoxolaner

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1093861-60-9, Afoxolaner [usan], 02l07h6d0u, Afoxolaner (usan), 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide, 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-1-naphthamide
    Molecular Formula
    C26H17ClF9N3O3
    Molecular Weight
    625.9  g/mol
    InChI Key
    OXDDDHGGRFRLEE-UHFFFAOYSA-N
    FDA UNII
    02L07H6D0U
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide
    2.1.2 InChI
    InChI=1S/C26H17ClF9N3O3/c27-15-8-13(7-14(9-15)25(31,32)33)23(26(34,35)36)10-20(39-42-23)18-5-6-19(17-4-2-1-3-16(17)18)22(41)37-11-21(40)38-12-24(28,29)30/h1-9H,10-12H2,(H,37,41)(H,38,40)
    2.1.3 InChI Key
    OXDDDHGGRFRLEE-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1C(=NOC1(C2=CC(=CC(=C2)Cl)C(F)(F)F)C(F)(F)F)C3=CC=C(C4=CC=CC=C43)C(=O)NCC(=O)NCC(F)(F)F
    2.2 Other Identifiers
    2.2.1 UNII
    02L07H6D0U
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 4-(5-(3-chloro-5-(trifluoromethyl)-phenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl)-n-(2- Oxo-2-((2,2,2-trifluoroethyl)amino)ethyl-1-naphthalenecarboxamide

    2.3.2 Depositor-Supplied Synonyms

    1. 1093861-60-9

    2. Afoxolaner [usan]

    3. 02l07h6d0u

    4. Afoxolaner (usan)

    5. 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide

    6. 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-1-naphthamide

    7. 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-n-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide

    8. Afoxolaner [usan:inn]

    9. Unii-02l07h6d0u

    10. Nexgard

    11. Afoxolaner [mi]

    12. Afoxolaner [inn]

    13. C26h17clf9n3o3

    14. Schembl119580

    15. Afoxolaner [green Book]

    16. Chembl2219412

    17. Dtxsid50148921

    18. Bcp21108

    19. Ex-a3267

    20. Afoxolaner [ema Epar Veterinary]

    21. Hy-16974

    22. Nexgard Spectra Conponent Afoxolaner

    23. Cs-0013215

    24. Afoxolaner Conponent Of Nexgard Spectra

    25. J3.498.573a

    26. D10361

    27. Q21051346

    28. 1-naphthalenecarboxamide, 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-4,5-dihydro-5- (trifluoromethyl)-3-isoxazolyl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-

    29. 1-naphthalenecarboxamide, 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-

    30. 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl(-n- (2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl(naphthalene-1-carboxamide

    31. 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)naphthalene-1-carboxamide

    32. 4-[(5r)-5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide

    2.4 Create Date
    2009-02-23
    3 Chemical and Physical Properties
    Molecular Weight 625.9 g/mol
    Molecular Formula C26H17ClF9N3O3
    XLogP36.7
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count13
    Rotatable Bond Count6
    Exact Mass625.0814726 g/mol
    Monoisotopic Mass625.0814726 g/mol
    Topological Polar Surface Area79.8 Ų
    Heavy Atom Count42
    Formal Charge0
    Complexity1040
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count1
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of flea infestation in dogs (Ctenocephalides felis and C. canis) for at least 5 weeks. The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

    Treatment of tick infestation in dogs (Dermacentor reticulatus, Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus). One treatment kills ticks for up to one month.

    Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

    Treatment of demodicosis (caused by Demodex canis).

    Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis).

    5 Pharmacology and Biochemistry
    5.1 ATC Code

    QP53BE01